Expect AbbVie’s story to move from ‘How much Humira?’ to ‘Who will it buy?’: analyst

AbbVie may not seem to most investors like the kind of company to chase down mammoth deals. But with Humira churning out billions every quarter, plus offshore cash on the way back to the U.S., it has the wherewithal to do just that, one analyst points out.Original Article